ASMB Relative Valuation
ASMB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASMB is overvalued; if below, it's undervalued.
Historical Valuation
Assembly Biosciences Inc (ASMB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.04. The fair price of Assembly Biosciences Inc (ASMB) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：35.38
Fair
-10.14
PE
1Y
3Y
5Y
Trailing
Forward
-6.69
EV/EBITDA
Assembly Biosciences Inc. (ASMB) has a current EV/EBITDA of -6.69. The 5-year average EV/EBITDA is -0.47. The thresholds are as follows: Strongly Undervalued below -3.95, Undervalued between -3.95 and -2.21, Fairly Valued between 1.26 and -2.21, Overvalued between 1.26 and 3.00, and Strongly Overvalued above 3.00. The current Forward EV/EBITDA of -6.69 falls within the Strongly Undervalued range.
-4.43
EV/EBIT
Assembly Biosciences Inc. (ASMB) has a current EV/EBIT of -4.43. The 5-year average EV/EBIT is -0.07. The thresholds are as follows: Strongly Undervalued below -2.97, Undervalued between -2.97 and -1.52, Fairly Valued between 1.38 and -1.52, Overvalued between 1.38 and 2.83, and Strongly Overvalued above 2.83. The current Forward EV/EBIT of -4.43 falls within the Strongly Undervalued range.
18.26
PS
Assembly Biosciences Inc. (ASMB) has a current PS of 18.26. The 5-year average PS is 11.12. The thresholds are as follows: Strongly Undervalued below -37.88, Undervalued between -37.88 and -13.38, Fairly Valued between 35.63 and -13.38, Overvalued between 35.63 and 60.13, and Strongly Overvalued above 60.13. The current Forward PS of 18.26 falls within the Historic Trend Line -Fairly Valued range.
-8.07
P/OCF
Assembly Biosciences Inc. (ASMB) has a current P/OCF of -8.07. The 5-year average P/OCF is -1.02. The thresholds are as follows: Strongly Undervalued below -4.27, Undervalued between -4.27 and -2.64, Fairly Valued between 0.61 and -2.64, Overvalued between 0.61 and 2.24, and Strongly Overvalued above 2.24. The current Forward P/OCF of -8.07 falls within the Strongly Undervalued range.
-8.00
P/FCF
Assembly Biosciences Inc. (ASMB) has a current P/FCF of -8.00. The 5-year average P/FCF is -1.32. The thresholds are as follows: Strongly Undervalued below -4.57, Undervalued between -4.57 and -2.94, Fairly Valued between 0.30 and -2.94, Overvalued between 0.30 and 1.93, and Strongly Overvalued above 1.93. The current Forward P/FCF of -8.00 falls within the Strongly Undervalued range.
Assembly Biosciences Inc (ASMB) has a current Price-to-Book (P/B) ratio of 3.03. Compared to its 3-year average P/B ratio of 2.62 , the current P/B ratio is approximately 15.50% higher. Relative to its 5-year average P/B ratio of 1.83, the current P/B ratio is about 65.27% higher. Assembly Biosciences Inc (ASMB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -48.87%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -59.36% , the current FCF yield is about -100.00% lower.
3.05
P/B
Median3y
2.62
Median5y
1.83
-10.08
FCF Yield
Median3y
-48.87
Median5y
-59.36
Competitors Valuation Multiple
The average P/S ratio for ASMB's competitors is 0.00, providing a benchmark for relative valuation. Assembly Biosciences Inc Corp (ASMB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 57.62%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ASMB increased by 123.51% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.84 to -7.88.
The secondary factor is the Revenue Growth, contributed 57.62%to the performance.
Overall, the performance of ASMB in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Assembly Biosciences Inc (ASMB) currently overvalued or undervalued?
What is Assembly Biosciences Inc (ASMB) fair value?
How does ASMB's valuation metrics compare to the industry average?
What is the current P/B ratio for Assembly Biosciences Inc (ASMB) as of Dec 05 2025?
What is the current FCF Yield for Assembly Biosciences Inc (ASMB) as of Dec 05 2025?
What is the current Forward P/E ratio for Assembly Biosciences Inc (ASMB) as of Dec 05 2025?